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EDITORIAL
Urinary podocytes: Lost and found alive
The glomerular podocyte is a terminally differentiated
cell that lines the outer aspect of the glomerular basement
membrane (GBM). It, therefore, forms the final barrier
to protein loss, which explains why podocyte injury is
typically associated with marked proteinuria. Indeed, all
forms of nephrotic syndrome are characterized by abnor-
malities in the podocyte [1]. Podocytes are injured in many
forms of human and experimental glomerular disease, in-
cluding minimal change disease, focal segmental glomeru-
losclerosis, membranous glomerulopathy, diabetes melli-
tus, and lupus nephritis [1]. Independent of the underlying
disease, the early events are characterized by molecular
alterations of the slit diaphragm without visible morpho-
logic changes or, more obviously, by a reorganization of
the foot process structure with fusion of filtration slits and
apical displacement of the SD [1].
From the standpoint of progressive glomerular disease,
it is important to recognize that if the early structural
changes are not reversed, severe and progressive glomeru-
lar damage develops [2]. This involves podocyte vacuoliza-
tion, pseudocyst formation, and detachment of podocytes
from the GBM, resulting in podocyte depletion. These
events underlie the formation of synechiae via attachment
of parietal epithelial cells of Bowman’s capsule to denuded
GBM areas [2]. These changes are irreversible and ulti-
mately lead to the development of glomerulosclerosis and
end-stage renal failure [2]. Studies in human diabetic ne-
phropathy [3–5], in the chronic puromycin model of glo-
merulosclerosis [6], and transforming growth factor-1
transgenic mice [7] collectively provided convincing evi-
dence for a correlation between the loss of podocyte and
the progression of glomerular diseases.
The detection of urinary podocytes does not come as
a surprise. In fact, several studies have previously docu-
mented the presence of urinary podocytes in a variety
of experimental and human glomerular diseases [8–17].
However, the viability of these cells was not determined.
More importantly, the cellular origin of these cells was
not entirely clear because these earlier studies relied on
the identification of podocytes as podocalyxin-positive
cells. This, however, is not sufficient to characterize the
cells as podocytes, because podocalyxin is widely ex-
pressed by other cells, including vascular endothelial cells
and platelets, and hematopoietic stem cells [18–20].
More recently Vogelmann et al [21] reported the uri-
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nary excretion of viable human podocytes in health and
renal disease and concluded that in active disease, viable
podocytes detach from the glomerular tuft due to local
environmental factors, rather than defects in the podo-
cytes, per se, whereas in healthy individuals mostly senes-
cent podocytes are shed.
The paper by Petermann et al [22] in this issue of Kid-
ney International takes the story a step further in that it
not only analyzes the identity and viability of urinary po-
docytes, but also correlated it with the podocyte number
in the kidneys from which these podocytes had been
shed. In addition, they analyzed the proliferative capac-
ity of the podocytes after they lost their connection with
the GBM. Urinary cells that had been harvested from
rats with experimental membranous nephropathy were
positive for a large variety of podocyte-specific markers,
including synaptopodin, nephrin, podocin, WT-1, and
GLEPP1. Another major finding of this study was the
fact that the urinary podocytes showed an initial prolifer-
ation during the first 5 days of in vitro culture. This
proliferative wave was then followed by dramatic apo-
ptosis leading to a net loss of cultured urinary podocytes.
Taken together, these results show that detached podo-
cytes are not only viable but also have retained or re-
gained a limited proliferative capacity [22].
So what do we learn from these studies? The finding
that urinary podocytes shed from glomeruli of diseased
rats can undergo cell division before they ultimately un-
dergo apoptosis has several implications. Most excitingly,
these studies shed new light on the dual role of the GBM
and/or the podocyte-GBM adhesion/signaling system.
The data by Petermann et al implies that the GBM pro-
vides signals that suppress both podocyte proliferation
and apoptosis. This idea is in line with novel results form
Huber et al [23], who showed that CD2AP null podocytes
are more susceptible to detachment-induced cell death
than wild-type podocytes. These results suggest that when
podocytes are no longer adherent to the GBM in vivo,
they regain the capacity to proliferate, but this comes at
the price of increased cell death. It would be interesting
to see whether the cultivation of the urinary podocytes
on isolated GBM preparations can prevent the apoptosis.
In summary, the present study by Petermann et al
established that adult podocytes retain or regain a certain
potential for replication and may, therefore, be not ter-
minally differentiated as generally assumed. These data
raise the intriguing possibly that it should be possible in
the future to establish conditions under which podocytes
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may transiently proliferate in vivo. This would eventually
allow the restoration of the normal podocyte number in
diseases with progressive podocyte loss, thereby pre-
venting the progression to ESRD. Clearly, there is a long
way to go, but the paper by Petermann et al represents
an important first step in this direction.
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